Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results
AUSTIN, Texas, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced financial and business results for the third quarter of 2019.
Third quarter 2019 net income from continuing operations was $0.5 million, or $0.03 per share. Total net income for the quarter after factoring in discontinued operations was also $0.5 million, or $0.03 per share. Operating cash burn for the quarter was approximately $2.1 million. Plus Therapeutics ended the quarter with approximately $16.8 million of cash and cash equivalents.
“Plus Therapeutics emerges from the third quarter with the financial strength, development focus and cost structure to achieve long-term viability and growth,” said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. “We believe our company is now poised to aggressively move its pipeline through important milestones and to eventual market leadership. We believe that our pipeline has the potential to produce drugs that may provide tremendous benefits to patients and shareholders alike.”
Third Quarter 2019 Corporate Highlights
- The Company received notification that a $4.6 million payment from the U.S. Department of Health and Human Services / Office of the Assistant Secretary for Preparedness and Response / Biomedical Advanced Research and Development Authority (“BARDA”) to reimburse the Company for work performed during fiscal years 2012 through 2019, will be paid in the fourth quarter.
- The Company completed an underwritten public offering with gross proceeds of approximately $15 million. The Company intends to use the net proceeds from the offering and from BARDA for research and development activities, working capital, potential debt restructuring and general corporate purposes.
- The Company completed its strategic initiative that included the adoption of its new name, Plus Therapeutics, Inc., and trading symbol as part of sharpened focus on product candidates that can potentially maximize returns for shareholders and make a clinically meaningful impact for patients. The Company is concentrating its development in ways that can leverage the U.S. FDA’s accelerated regulatory pathways and enable the Company to apply its in-house expertise in nanoparticle drug design, complex formulation, and drug manufacturing to scale-up.
- The Company announced that its initial development focus will be on DocePLUS (formerly ATI-1123) -- a complex, injectable, patented, albumin-stabilized pegylated liposomal docetaxel -- for which a U.S. Phase 1 clinical trial has been completed and published. The Company has previously announced that it received feedback from the U.S. FDA that a 505(b)(2) new drug application appears to be an acceptable regulatory approach for DocePLUS. The Company intends to submit a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy to the U.S. FDA in the second half of 2019.
- The Company moved its headquarters from San Diego, CA, to Austin, TX, while maintaining a manufacturing facility in San Antonio, TX. The move was driven in part by significant incentives offered by the State of Texas, whose Cancer Prevention & Research Institute is second only to the federal government in public funding of cancer research.
Third Quarter 2019 Financial Performance Highlights
- Q3 2019 operating cash burn was $2.1 million, compared to $2.6 million for Q3 2018.
- Q3 2019 contract revenues were $4.8 million, compared to $0.5 million for Q3 2018.
- Q3 2019 net income from continuing operations was $0.5 million or $ 0.03 per share, compared to a net loss of ($1.4) million or ($22.27) per share for Q3 2018.
- Q3 2019 total net income after factoring in discontinued operations was $0.5 million or $ 0.03 per share compared to a total net loss of ($2.3) million or ($ 27.63) per share for Q3 2018, after factoring in discontinued operations.
- Cash and cash equivalents and debt principal balances at September 30, 2019, were approximately $16.8 million and $9.3 million, respectively.
Investor Call Today at 5 p.m. Eastern Time
The Company plans to hold a conference call and live audio webcast at 5 p.m. Eastern Time to discuss its financial results and provide a general business update.
Event: Plus Therapeutics Third Quarter 2019 Conference Call and Webcast
Date: Today, November 14, 2019
Time: 5 p.m. Eastern Time
Live Call: Dial-In +1.877.402.3914 and Conference ID 2486739
Live Webcast: http://ir.plustherapeutics.com/events/default.aspx
Replay (available 2 hours after the Live Call): Dial-In +1.855.859.2056 and Conference ID 9998475
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.
Our lead product candidate, DocePLUS, is a protein-stabilized PEGylated liposomal formulation of docetaxel, for which the process of preparation is patented. The active pharmaceutical ingredient, docetaxel, was approved by the U.S. FDA in 1999 and commonly used for treating cancers of the breast, head, neck, stomach, prostate, and lung.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop a market leading position; and the potential for, and timing of, the Company’s submission of a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the U.S. FDA does not accept the Company’s submission of a Phase 2 clinical trial protocol in Small Cell Lung Cancer patients with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy; the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
PLUS THERAPEUTICS, INC.
(previously known as Cytori Therapeutics, Inc.)
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands, except share and par value data)
|As of September 30,
|As of December 31,
|Cash and cash equivalents||$||16,834||$||5,261|
|Other current assets||502||785|
|Current assets held for sale||—||3,277|
|Total current assets||22,264||9,648|
|Property and equipment, net||2,209||2,299|
|Operating lease right-of-use assets||818||—|
|Noncurrent assets held for sale||—||11,633|
|Liabilities and Stockholders’ Equity|
|Accounts payable and accrued expenses||$||3,334||$||2,777|
|Operating lease liability||156||—|
|Term loan obligations, net of discount||10,937||14,202|
|Current liabilities held for sale||—||580|
|Total current liabilities||14,427||17,559|
|Other noncurrent liabilities||38||46|
|Noncurrent operating lease liability||684||—|
|Noncurrent liabilities held for sale||—||245|
|Commitments and contingencies (Notes 8 and 9)|
|Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,959 and 4,606 shares issued and outstanding in 2019 and 2018, respectively||—||—|
|Common stock, $0.001 par value; 100,000,000 shares authorized; 2,841,588 and 296,609 shares issued and outstanding in 2019 and 2018, respectively||3||—|
|Additional paid-in capital||426,311||418,390|
|Accumulated other comprehensive income||—||1,218|
|Total stockholders’ equity||160||5,225|
|Total liabilities and stockholders’ equity||$||25,715||$||23,991|
PLUS THERAPEUTICS, INC.
(previously known as Cytori Therapeutics, Inc.)
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(LOSS)
(in thousands, except share and per share data)
|For the Three Months Ended September 30,||For the Nine Months Ended September 30,|
|Government contracts and other||$||4,771||$||454||$||5,810||$||2,270|
|Research and development||921||1,226||3,636||3,887|
|Sales and marketing||94||118||305||596|
|General and administrative||1,076||1,337||3,313||4,639|
|Total operating expenses||2,091||2,681||7,254||9,122|
|Operating income (loss)||2,680||(2,227||)||(1,444||)||(6,852||)|
|Other income (expense):|
|Change in fair value of warrants||(561||)||1,676||(69||)||1,676|
|Warrant issuance cost||(1,233||)||(343||)||(1,233||)||(343||)|
|Total other income (expense)||(2,154||)||831||(2,759||)||(16||)|
|Income (loss) from continuing operations||$||526||$||(1,396||)||$||(4,203||)||$||(6,868||)|
|Loss from discontinued operations||—||(934||)||(7,568||)||(3,530||)|
|Net Income (loss)||$||526||$||(2,330||)||$||(11,771||)||$||(10,398||)|
|Income (Loss) from continuing operations||$||526||$||(1,396||)||$||(4,203||)||$||(6,868||)|
|Beneficial conversion feature for convertible preferred stock||(554||)||(2,487||)||(554||)||(2,487||)|
|Net loss allocable to common stockholders - continuing operations||$||(28||)||$||(3,883||)||$||(4,757||)||$||(9,355||)|
|Net loss allocable to common stockholders - discontinued operations||$||—||$||(934||)||$||(7,568||)||$||(3,530||)|
|Basic and diluted net loss per share attributable to common stockholders from continuing operations||$||(0.03||)||$||(22.27||)||$||(8.78||)||$||(67.09||)|
|Basic and diluted net loss per share attributable to common stockholders from discontinued operations||$||—||$||(5.36||)||$||(13.97||)||$||(25.31||)|
|Net loss per share, basic and diluted||$||(0.03||)||$||(27.63||)||$||(22.75||)||(92.40||)|
|Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders||826,548||174,324||541,777||139,452|
|Comprehensive income (loss):|
|Net income (loss)||$||526||$||(2,330||)||$||(11,771||)||$||(10,398||)|
|Other comprehensive loss – foreign currency translation adjustments||—||(55||)||—||(205||)|
|Comprehensive income (loss)||$||526||$||(2,385||)||$||(11,771||)||$||(10,603||)|
PLUS THERAPEUTICS, INC.
(previously known as Cytori Therapeutics, Inc.)
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
|For the Nine Months Ended September 30,|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Noncash lease expense||22||—|
|Depreciation and amortization||778||1,465|
|Amortization of deferred financing costs and debt discount||354||383|
|Provision for excess inventory||—||433|
|Change in fair value of warrants||69||(1,676||)|
|Allocation of issuance costs associated with warrants||1,233||343|
|Share-based compensation expense||106||325|
|Loss on asset disposal||—||23|
|Loss on sale of business||6,306||—|
|Increases (decreases) in cash caused by changes in operating assets and liabilities:|
|Other current assets||252||514|
|Accounts payable and accrued expenses||(95||)||(1,274||)|
|Other long-term liabilities||54||(24||)|
|Net cash used in operating activities||(6,942||)||(9,487||)|
|Cash flows from investing activities:|
|Purchases of property and equipment||(8||)||(128||)|
|Proceeds from sale of business, net||2,789||—|
|Net cash provided by (used in) investing activities||2,781||(128||)|
|Cash flows from financing activities:|
|Principal payment of long-term obligations||(642||)||—|
|Payment of financing lease liability||(75||)||—|
|Proceeds from exercise of warrants||491|
|Proceeds from sale of common stock, net of offering cost||15,964||6,246|
|Net cash provided by financing activities||15,738||6,246|
|Effect of exchange rate changes on cash and cash equivalents||(4||)||(10||)|
|Net increase (decrease) in cash and cash equivalents||11,573||(3,379||)|
|Cash, cash equivalents, and restricted cash at beginning of period||5,301||10,225|
|Cash, cash equivalents, and restricted cash at end of period||$||16,874||$||6,846|
|Supplemental disclosure of cash flows information:|
|Cash paid during period for:|
|Supplemental schedule of non-cash investing and financing activities:|
|Proceeds from sales of business, net, paid directly to lender for principal payment of long-term obligations||$||3,050||$||—|
|Offering cost paid in warrants||$||213||$||—|
|Unpaid offering costs||$||403||$||—|
|Reclass of warrants upon exercise from liability to equity||$||794||$||—|
Source: Plus Therapeutics, Inc.